Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Russell Scott, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael d'Emden, Dana Tse, Marja-Ruita Taskinen, Christian Ehnholm, Anthony Keech
DIABETES CARE | AMER DIABETES ASSOC | Published : 2009
This Study was supported by a grant from Laboratoires Fournier SA, Dijon, France, and by the National Health and Medical Research Council (NHMRC) of Australia and was coordinated independently by the NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia, and overseen by the study management committee.R.O., G.F., M.-R.T., C.E., and A.K. have had the costs of participation in scientific meetings and/or contributions to advisory boards or doing Other research reimbursed by Laboratoires Fournier (now a division of Solvay). A.K. is a listed applicant on a patent application in relation to some other findings related to this research. No other Potential conflicts of interest relevant to this article were reported.